Shay Capital’s Relmada Therapeutics RLMD Stock Holding History

Shay Capital’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-175,547	Closed	-$569K	–	408
2024 Q3	$569K	Buy	+175,547	New	+$569K	0.08%	148

Other funds holding RLMD

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Shay Capital's RLMD Position: Q4 2024 in Review

Shay Capital sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 175,547 shares — an estimated $569K sold.

Shay Capital first reported a position in RLMD in Q3 2024 and held it in 1 quarter. The position peaked at $569K in Q3 2024. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

Shay Capital reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
Shay Capital sold 175,547 Relmada Therapeutics shares in Q4 2024, an estimated $569K.
Shay Capital first reported a position in Relmada Therapeutics in Q3 2024 and held it in 1 quarter.
Shay Capital's Relmada Therapeutics position peaked at $569K in Q3 2024.
48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Shay Capital's 13F filing for Q4 2024, filed 14 Feb 2025.